VivoSeq
Oncology

B-Cell Malignancies

7

Pipeline Programs↗

34

Active Trials↗

28

Companies Involved↗

B-cell Malignancies is an early-stage landscape with 7 programs across 28 companies. The most active players are Incyte, BeiGene, Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

30/100

Mech. Concentration

100/100

Completion Rate

65/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

2 programs

Phase 2BeiGene logo

BeiGene

0 programs

PreclinicalRegeneron logo

Regeneron

0 programs

PreclinicalT

TG Therapeutics, Inc.

0 programs

PreclinicalGilead logo

Gilead

0 programs

PreclinicalF

Fundamenta Therapeutics, Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSCell therapy133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 31% of 13 pipeline programs.

Analysis

Trial Status

92

clinical trials

Unknown status26 · 28%
Completed20 · 22%
Recruiting19 · 21%
Active, not recruiting13 · 14%
Terminated9 · 10%
Withdrawn2 · 2%
Other3 · 3%

Clinical Trials

Trial Activity

92 trials

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Recruiting·CCancer Research UK·Phase 1/2·NCT06045910·84 enrolled
JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies
Recruiting·—·N/A·NCT07065279·36 enrolled
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Recruiting·MMedical College of Wisconsin·Phase 1·NCT05990465·12 enrolled
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
Recruiting·TTransThera Sciences (Nanjing), Inc.·Phase 1·NCT05683717·37 enrolled
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Recruiting·UUmoja Biopharma·Phase 1·NCT06528301·106 enrolled
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Recruiting·AbbVie logoAbbVie·Phase 1·NCT05618028·150 enrolled
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Recruiting·BeiGene logoBeiGene·Phase 1/2·NCT05294731·146 enrolled
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Recruiting·GGrit Biotechnology·Phase 1/2·NCT06948981·46 enrolled
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT06014762·120 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Recruiting·MMedical College of Wisconsin·Phase 1/2·NCT04186520·100 enrolled
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Recruiting·AstraZeneca logoAstraZeneca·Phase 1/2·NCT06542250·174 enrolled
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Recruiting·BBeOne Medicines·Phase 1/2·NCT05006716·614 enrolled
CD19/79b Bi-specific CAR-T Cells Targeting B Cell Malignancies
Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT05436509·60 enrolled
4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia
Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT04430530·100 enrolled
Universal 4SCAR19U T Cell Therapy for the Treatment of Relapsed and Refractory B Cell Malignancies
Recruiting·SShenzhen Geno-Immune Medical Institute·Phase 1·NCT05995015·30 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)